{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:59:49Z","timestamp":1794286789058,"version":"4.9.0"},"reference-count":269,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":5431,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015693","name":"Purdue Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.jpainsymman.2004.07.005","type":"journal-article","created":{"date-parts":[[2005,3,18]],"date-time":"2005-03-18T09:42:44Z","timestamp":1111138964000},"page":"297-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":223,"title":["Buprenorphine: Considerations for Pain Management"],"prefix":"10.1016","volume":"29","author":[{"given":"Rolley E.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Fudala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2004.07.005_bib1","series-title":"Goodman and Gilman's: The pharmacological basis of therapeutics","first-page":"569","article-title":"Opioid analgesics","author":"Gutstein","year":"2001"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib2","unstructured":"Reckitt Benckiser Pharmaceuticals, Inc. Buprenex Product Insert, Richmond, VA, 2002."},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: A review of its pharmacological properties and therapeutic efficacy","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib4","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1021\/ja00989a030","article-title":"Novel analgesics and molecular rearrangements in the morphinethebaine group. I. Ketones derived from 6,14-endo-ethenotetrahydrothebaine","volume":"89","author":"Bentley","year":"1967","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jps.2600730225","article-title":"Stability of the 6, 14-endo-ethanotetrahydro-oripavine analgesics: Acid-catalyzed rearrangement of buprenorphine","volume":"73","author":"Cone","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1023\/A:1016340106299","article-title":"Buprenorphine is an antagonist at the kappa opioid receptor","volume":"2","author":"Richards","year":"1985","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-2999(85)90379-6","article-title":"In vivo opiate receptor binding of oripavines to mu, delta, and kappa sites in rat brain as determined by an ex vivo labeling method","volume":"114","author":"Richards","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0014-2999(88)90543-2","article-title":"Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice","volume":"151","author":"Leander","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0166-2236(93)90194-Q","article-title":"Molecular biology of opioid receptors","volume":"16","author":"Reisine","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib12","series-title":"Problems of drug dependence. NIDA Research Monograph 41","first-page":"45","article-title":"Progress report of the NIDA Addiction Research Center","author":"Jasinski","year":"1982"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003088-198308040-00004","article-title":"Clinical pharmacokinetics of narcotic agonist-antagonist drugs","volume":"8","author":"Bullingham","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib14","series-title":"PDR Physicians' Desk Reference","year":"2004"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib15","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/0024-3205(81)90529-4","article-title":"Buprenorphine: Characteristics of binding sites in the rat central nervous system","volume":"29","author":"Villiger","year":"1981","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/j.1471-4159.1982.tb06662.x","article-title":"Buprenorphine: High affinity binding to dorsal spinal cord","volume":"38","author":"Villiger","year":"1982","journal-title":"J Neurochem"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib17","series-title":"Buprenorphine: combatting drug abuse with a unique opioid","first-page":"19","article-title":"Buprenorphine: A review of the binding literature","author":"Rothman","year":"1995"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bja\/57.2.192","article-title":"Clinical actions of fentanyl and buprenorphine. The significance of receptor binding","volume":"57","author":"Boas","year":"1985","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(25)33306-9","article-title":"Buprenorphine: Differential interaction with opiate receptor subtypes in vivo","volume":"223","author":"Sade\u00e9","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0160-5402(79)90018-4","article-title":"Evaluation of antinociceptive activity using electrical stimulation of the tooth pulp in the conscious dog","volume":"2","author":"Skingle","year":"1979","journal-title":"J Pharmac Methods"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1476-5381.1980.tb07939.x","article-title":"Further studies on opiate receptors that mediate antinociception: Tooth pulp stimulation in the dog","volume":"70","author":"Skingle","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.1987.tb11281.x","article-title":"Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists","volume":"91","author":"Hayes","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib24","series-title":"Buprenorphine: combating drug abuse with a unique opioid","first-page":"31","article-title":"Update on the general pharmacology of buprenorphine","author":"Cowan","year":"1995"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine, an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1476-5381.1981.tb10473.x","article-title":"In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions","volume":"74","author":"Dum","year":"1981","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1476-5381.1980.tb07041.x","article-title":"A classification of opiate receptors that mediate antinociception in animals","volume":"69","author":"Tyers","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1476-5381.1983.tb09417.x","article-title":"Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat","volume":"78","author":"Bryant","year":"1983","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib30","series-title":"Buprenorphine: An alternative treatment for opioid dependence. NIDA Research Monograph No 121","first-page":"12","article-title":"Behavioral pharmacology of buprenorphine: Issues relevant to its potential in treating drug abuse","author":"Woods","year":"1992"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(91)90485-9","article-title":"Buprenorphine and morphine cause antinociception by different transduction mechanisms","volume":"195","author":"Wheeler-Aceto","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib32","series-title":"Endogenous and exogenous opiate agonists and antagonists. Proceedings of the International Narcotic Research Club Conference","first-page":"387","article-title":"Biphasic dose response to buprenorphine in the rat tail flick assay: Effect of naloxone pretreatment","author":"Rance","year":"1979"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0091-3057(78)90370-2","article-title":"Discriminative stimulus properties of narcotic analgesic drugs","volume":"9","author":"Colpaert","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-3565(25)21937-1","article-title":"Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: Quantitative antagonism by naloxone","volume":"229","author":"Shannon","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib36","series-title":"Proceedings of the 39th Annual Scientific Meeting of the Committee on Problems of Drug Dependence","first-page":"420","article-title":"Narcotic-reinforced responding: A rapid screening procedure","author":"Woods","year":"1977"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0091-3057(81)90180-5","article-title":"Buprenorphine self-administration by rhesus monkey","volume":"15","author":"Mello","year":"1981","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib38","series-title":"Problems of drug dependence. NIDA Research Monograph 41","first-page":"208","article-title":"Dependence potential of buprenorphine studied in rhesus monkeys","author":"Yanagita","year":"1982"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0022-3565(25)21772-4","article-title":"Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids","volume":"229","author":"Young","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)24396-8","article-title":"Comparison of opioid self-injection and disruption of schedule-controlled performance in the baboon","volume":"238","author":"Lukas","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(81)90163-1","article-title":"Buprenorphine: Demonstration of physical dependence liability","volume":"70","author":"Dum","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0376-8716(85)90059-6","article-title":"Substitution and primary dependence studies in animals","volume":"14","author":"Woods","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0143-4179(84)90016-7","article-title":"The suppression of deprivation and antagonist-induced withdrawal in morphinedependent rhesus monkeys","volume":"5","author":"Gmerek","year":"1984","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib44","series-title":"Primary addiction study, UM952. Problems of drug dependence 1975. Proceedings of the Thirty-Seventh Annual Scientific Meeting, Committee on Problems of Drug Dependence","author":"Swain","year":"1975"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib45","unstructured":"Registry of Toxic Effects of Chemical Substances, MDL Information Systems, Inc.: San Leandro, CA. 2002."},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib46","first-page":"509","article-title":"Buprenorphine: Toxicological studies of buprenorphine: II. Teratogenicity in rat","volume":"13","author":"Mori","year":"1982","journal-title":"Iyakuhin Kenkyu"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib47","first-page":"33","article-title":"Effects of prenatal methadone on the rest-activity cycle of the pre-weanling rat","volume":"1","author":"Hutchings","year":"1979","journal-title":"Neurobehav Toxicol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0091-3057(96)00287-0","article-title":"Prenatal administration of buprenorphine in the rat: Effects on the rest-activity cycle at 22 and 30 days of age","volume":"55","author":"Hutchings","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0091-3057(79)90327-7","article-title":"Development of motor activity in young rats following perinatal methadone exposure","volume":"10","author":"Zagon","year":"1979","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib50","series-title":"Neurobehavioral teratology","first-page":"197","article-title":"An overview of the neurobehavioral sequelae of perinatal opioid exposure","author":"Zagon","year":"1984"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0892-0362(91)90006-I","article-title":"The effect of prenatal methadone exposure on development and nociception during the early postnatal period of the rat","volume":"13","author":"Enters","year":"1991","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib52","first-page":"532","article-title":"Buprenorphine: Toxicological studies of buprenorphine: III. Perinatal and postnatal study in rat","volume":"13","author":"Mori","year":"1982","journal-title":"Iyakuhin Kenkyu"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib53","series-title":"MIMS Annual","year":"2003"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02255474","article-title":"Effect of prenatal opioid exposure on cholinergic development","volume":"7","author":"Robinson","year":"2000","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-1681.1989.tb01541.x","article-title":"Effects of subacute opioid administration during late pregnancy in the rat on the initiation, duration and outcome of parturition and maternal levels of oxytocin and arginine vasopressin","volume":"16","author":"Evans","year":"1989","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0892-0362(94)00079-S","article-title":"Prenatal administration of buprenorphine using the osmotic minipump: A preliminary study of maternal and offspring toxicity and growth in the rat","volume":"17","author":"Hutchings","year":"1995","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-3565(24)29441-6","article-title":"Effect of perinatal buprenorphine exposure on development in the rat","volume":"298","author":"Robinson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib58","series-title":"Opiates and endogenous opioid peptides. Proceedings of the International Narcotics Research Club Meeting, Aberdeen, United Kingdom, July 19\u201322, 1976","first-page":"295","article-title":"The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics","author":"Hambrook","year":"1976"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib59","series-title":"Opiates and endogenous opiate peptides. Proceedings of the International Narcotics Research Club Meeting, Aberdeen, United Kingdom, July 19\u201322, 1976","first-page":"447","article-title":"Significance of physiochemical properties of opiates for in vitro testing","author":"W\u00fcster","year":"1976"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0022-3565(25)33173-3","article-title":"The affinity of morphine for its pharmacologic receptor in vivo","volume":"222","author":"Tallarida","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3565(25)12294-5","article-title":"Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans","volume":"276","author":"Eissenberg","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0378-4347(91)80537-M","article-title":"Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: Application to human and rabbit pharmacokinetic studies","volume":"570","author":"Ho","year":"1991","journal-title":"J Chromatogr"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine kinetics","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/bja\/54.1.37","article-title":"Single-dose comparison of buprenorphine 0.3 and 0.6 mg i.v. given after operation: Clinical effects and plasma concentration","volume":"54","author":"Watson","year":"1982","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib65","series-title":"Buprenorphine: Combatting drug abuse with a unique opioid","first-page":"113","article-title":"Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans","author":"Walter","year":"1995"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib66","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib67","first-page":"818","article-title":"Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4","volume":"26","author":"Kobayashi","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0090-9556(25)06808-4","article-title":"Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine","volume":"15","author":"Mistry","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-9556(25)08299-6","article-title":"Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats","volume":"22","author":"Ohtani","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3565(25)24425-1","article-title":"Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling","volume":"272","author":"Ohtani","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.2600810102","article-title":"Drug delivery via the mucous membranes of the oral cavity","volume":"81","author":"Harris","year":"1992","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib72","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/00498258509045363","article-title":"Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant","volume":"15","author":"Pontani","year":"1985","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib73","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3565(24)36604-2","article-title":"Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine","volume":"281","author":"Ohtani","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/00498258109045291","article-title":"Biliary excretion, metabolism, and enterohepatic circulation of buprenorphine","volume":"11","author":"Brewster","year":"1981","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","article-title":"The metabolism and excretion of buprenorphine in humans","volume":"12","author":"Cone","year":"1984","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1981.tb01189.x","article-title":"Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis","volume":"12","author":"Bullingham","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib77","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1982.tb01434.x","article-title":"Sublingual buprenorphine used postoperatively: Ten-hour plasma drug concentration analysis","volume":"13","author":"Bullingham","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0009-9236(96)90173-3","article-title":"Buprenorphine and naloxone interactions in opiate-dependent volunteers","volume":"60","author":"Mendelson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib79","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib81","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1093\/clinchem\/43.12.2292","article-title":"Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: Application to pharmacokinetics of sublingual buprenorphine","volume":"43","author":"Everhart","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib82","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","article-title":"Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations","volume":"39","author":"Nath","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(99)00012-5","article-title":"Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet","volume":"56","author":"Schuh","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib84","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.2042-7158.1989.tb06374.x","article-title":"The systemic availability of buprenorphine administered by nasal spray","volume":"41","author":"Eriksen","year":"1989","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(00)00499-3","article-title":"Intranasal absorption of buprenorphine\u2014in vivo bioavailability study in sheep","volume":"205","author":"Lindhardt","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib86","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4065\/70.6.581","article-title":"Transcutaneous drug delivery: A practical review","volume":"70","author":"Berti","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib87","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jps.2600830204","article-title":"Transdermal delivery of buprenorphine through cadaver skin","volume":"83","author":"Roy","year":"1994","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib88","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2165\/00003495-200363190-00004","article-title":"Transdermal buprenorphine. A viewpoint by Rudolf Likar","volume":"63","author":"Likar","year":"2003","journal-title":"Drugs"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2004.07.005_bib89","first-page":"9","article-title":"Buprenorphine and the transdermal system: The ideal match in pain management","volume":"133","author":"Budd","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib90","first-page":"1026","article-title":"Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days","volume":"41","author":"Reidenberg","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib91","first-page":"1027","article-title":"Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days","volume":"41","author":"Reidenberg","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib92","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/bja\/64.3.276","article-title":"Buprenorphine disposition in patients with renal impairment: Single and continuous dosing, with special reference to metabolites","volume":"64","author":"Hand","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib93","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2044.1985.tb11063.x","article-title":"Buprenorphine in end stage renal failure","volume":"41","author":"Summerfield","year":"1985","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib94","first-page":"P2","article-title":"Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment","volume":"69","author":"Lasseter","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib95","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2125.1989.tb05418.x","article-title":"Pharmacokinetics of intravenous buprenorphine in children","volume":"28","author":"Olkkola","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib96","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2125.1993.tb04220.x","article-title":"The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates","volume":"36","author":"Barrett","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","article-title":"Responsible prescribing of opioids for the management of chronic pain","volume":"63","author":"Nicholson","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib98","first-page":"82","article-title":"Past and current status of pain research and therapy","volume":"5","author":"Bonica","year":"1986","journal-title":"Semin Anesthesia"},{"issue":"Suppl 1","key":"10.1016\/j.jpainsymman.2004.07.005_bib99","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0304-3959(99)00148-7","article-title":"Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients","volume":"82","author":"Woolf","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib100","first-page":"241","article-title":"Clinical aspects of pain","volume":"3","author":"Sternbach","year":"1978"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0885-3924(95)00189-1","article-title":"Comprehensive pretreatment and outcome assessment for chronic opioid therapy in nonmalignant pain","volume":"11","author":"Jamison","year":"1996","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib102","unstructured":"American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain, 2001. Available at www.painmed.org\/productpub\/statements\/pdfs\/definition.pdf. Accessed on September 21, 2003."},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib103","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0885-3924(93)90155-O","article-title":"Addiction in the treatment of pain: Significance, recognition, and management","volume":"8","author":"Savage","year":"1993","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib104","first-page":"S46","article-title":"Chronic opioid therapy in non-malignant pain","volume":"5","author":"Portenoy","year":"1990","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/scientificamerican0290-27","article-title":"The tragedy of needless pain","volume":"262","author":"Melzack","year":"1990","journal-title":"Sci Am"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib106","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1399-6576.1980.tb01584.x","article-title":"Double-blind, multi-dose comparison of buprenorphine and morphine in postoperative pain","volume":"24","author":"Tigerstedt","year":"1980","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib107","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/j.1552-4604.1981.tb01774.x","article-title":"Multidose\/observational, comparative clinical analgesic evaluation of buprenorphine","volume":"21","author":"Mok","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/j.1552-4604.1981.tb01761.x","article-title":"The study of analgesics following single and repeated doses","volume":"21","author":"Wang","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib109","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003495-199141030-00002","article-title":"Opioid agonist-antagonist drugs in acute and chronic pain states","volume":"41","author":"Hoskin","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2044.1980.tb05125.x","article-title":"Buprenorphine in postoperative pain: Results in 7500 patients","volume":"35","author":"Harcus","year":"1980","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/bja\/49.3.251","article-title":"Buprenorphine: A new potent long-lasting synthetic analgesic. Comparison with morphine","volume":"49","author":"Downing","year":"1977","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib112","first-page":"1647","article-title":"Prevention of postoperative pain using buprenorphine, morphine or pethidine","volume":"102","author":"Isaksen","year":"1982","journal-title":"Tidsskr Norski Laegeforen"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0310057X8401200403","article-title":"A comparison of morphine and buprenorphine for analgesia after abdominal surgery","volume":"12","author":"Bradley","year":"1984","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib114","first-page":"55","article-title":"Comparison of buprenorphine and morphine: A multicenter, multidose study in patients with severe postoperative pain","volume":"28","author":"Ouellette","year":"1986","journal-title":"Contemp Surg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib115","first-page":"359","article-title":"Intramuscular buprenorphine compared with morphine for postoperative analgesia","volume":"71","author":"Payne","year":"1987","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1445-2197.1987.tb01345.x","article-title":"A double-blind comparison of the relative efficacy, side effects and cost of buprenorphine and morphine in patients after cardiac surgery","volume":"57","author":"Rabinov","year":"1987","journal-title":"Aust NZ J Surg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib117","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/bja\/49.9.913","article-title":"Comparison of buprenorphine, pethidine and pentazocine for the relief of pain after operation","volume":"49","author":"Hovell","year":"1977","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib118","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/50.6.599","article-title":"A comparison of buprenorphine and pethidine for immediate postoperative pain relief by the i.v. route","volume":"50","author":"Kamel","year":"1978","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib119","first-page":"352","article-title":"Double-blind, multiple-dose comparison of buprenorphine and meperidine for postoperative pain following major abdominal surgery","volume":"46","author":"Ouellette","year":"1989","journal-title":"Current Ther Res"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1365-2044.1981.tb08867.x","article-title":"High dose buprenorphine for postoperative analgesia","volume":"36","author":"Budd","year":"1981","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib121","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/j.1875-9114.1986.tb03481.x","article-title":"Crossover trials in clinical analgesic assays: Studies of buprenorphine and morphine","volume":"6","author":"Wallenstein","year":"1986","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib122","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2044.1986.tb12710.x","article-title":"Epidural buprenorphine for postoperative analgesia. A controlled comparison with epidural morphine","volume":"41","author":"Wolff","year":"1986","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib123","first-page":"361","article-title":"Continuous-plus-on-demand epidural infusion of buprenorphine versus morphine in postoperative treatment of pain","volume":"37","author":"Chrubasik","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-2007-1003444","article-title":"Serum morphine concentrations in epidural, on-demand morphine infusion","volume":"19","author":"Chrubasik","year":"1984","journal-title":"Anasth Intensivther Notfallmed"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1399-6576.1986.tb02497.x","article-title":"Postoperative pain relief with high-dose epidural buprenorphine: A double-blind study","volume":"30","author":"Gundersen","year":"1986","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib126","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1213\/00000539-198406000-00007","article-title":"Epidural buprenorphine\u2014a double-blind study of postoperative analgesia and side effects","volume":"63","author":"Lanz","year":"1984","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib127","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2044.1988.tb05482.x","article-title":"Intrathecal buprenorphine for postoperative analgesia in the elderly patient","volume":"43","author":"Capogna","year":"1988","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib128","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/bja\/59.11.1364","article-title":"Constant I.V. infusions of nalbuphine or buprenorphine for pain after abdominal surgery","volume":"59","author":"Pugh","year":"1987","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib129","first-page":"27","article-title":"A comparison of buprenorphine and pentazocine for the relief of postoperative pain","volume":"69","author":"Freedman","year":"1986","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/bja\/55.1.21","article-title":"Comparison between buprenorphine and pentazocine given i.v. on demand in the control of postoperative pain","volume":"55","author":"Harmer","year":"1983","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib131","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2044.1979.tb06325.x","article-title":"Analgesic effects of sublingual buprenorphine","volume":"34","author":"Edge","year":"1979","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib132","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2044.1979.tb06339.x","article-title":"Relief of pain after surgery. A comparison of sublingual buprenorphine and intramuscular papaveretum","volume":"34","author":"Fry","year":"1979","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib133","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1399-6576.1985.tb02181.x","article-title":"Sublingual buprenorphine for premedication and postoperative pain relief in orthopaedic surgery","volume":"29","author":"Risbo","year":"1985","journal-title":"Acta Anaesehesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib134","first-page":"493","article-title":"Periodic sublingual buprenorphine for pain relief after upper abdominal surgery","volume":"38","author":"Hayakawa","year":"1989","journal-title":"Jap J Anesthesiol [Masui]"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1213\/00000539-198666020-00008","article-title":"Pain relief after major abdominal surgery: A double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine","volume":"66","author":"Carl","year":"1987","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib136","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1399-6576.1999.430112.x","article-title":"Intra-articular buprenorphine after knee arthroscopy. A randomized, prospective, double-blind study","volume":"43","author":"Varrassi","year":"1999","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib137","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1399-6576.1993.tb03729.x","article-title":"Caudal buprenorphine for postoperative analgesia in children: A comparison with intramuscular buprenorphine","volume":"37","author":"Girotra","year":"1993","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib138","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1399-6576.1982.tb01776.x","article-title":"Analgesia for circumcision in children: A comparison of caudal bupivacaine and intramuscular buprenorphine","volume":"26","author":"May","year":"1982","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib139","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2044.1990.tb14788.x","article-title":"Postoperative analgesia in children who have genito-urinary surgery: A comparison between caudal buprenorphine and bupivacaine","volume":"45","author":"Girotra","year":"1990","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1399-6576.1992.tb03475.x","article-title":"Application of sublingual buprenorphine in combination with naproxen or paracetamol for post-operative pain relief in cholecystectomy patients in a double-blind study","volume":"36","author":"Witjes","year":"1992","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib141","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1399-6576.1990.tb03044.x","article-title":"Sublingual buprenorphine as postoperative analgesic: A double-blind comparison with pethidine","volume":"34","author":"Moa","year":"1990","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib142","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.2.6195.895","article-title":"Comparison of buprenorphine and pethidine given intravenously on demand to relieve postoperative pain","volume":"2","author":"Chakravarty","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib143","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/bja\/54.3.279","article-title":"Patient administration of I.V. buprenorphine for postoperative pain relief using the \u201cCardiff\u201d demand analgesia apparatus","volume":"54","author":"Gibbs","year":"1982","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib144","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/bmj.286.6366.680","article-title":"Intramuscular on demand analgesia: Double blind controlled trial of pethidine, buprenorphine, morphine, and meptazinol","volume":"286","author":"Harmer","year":"1983","journal-title":"Br Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0952-8180(91)90158-J","article-title":"Postoperative pain management and respiratory depression after thoracotomy: A comparison of intramuscular piritramide and intravenous patient-controlled analgesia using fentanyl or buprenorphine","volume":"3","author":"Lehmann","year":"1991","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0376-8716(93)90036-P","article-title":"The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand","volume":"33","author":"Robinson","year":"1993","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib147","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00542434","article-title":"Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine","volume":"34","author":"Lehman","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib148","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1185\/03007998609110432","article-title":"Comparison of intramuscular buprenorphine and a buprenorphine\/naloxone combination in the treatment of post-operative pain","volume":"10","author":"Vanacker","year":"1986","journal-title":"Curr Med Res Opinion"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib149","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/030006058601400306","article-title":"A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients","volume":"14","author":"Rolly","year":"1986","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib150","doi-asserted-by":"crossref","first-page":"315S","DOI":"10.1111\/j.1365-2125.1979.tb04706.x","article-title":"A trial of sublingual buprenorphine in cancer pain","volume":"7","author":"Robbie","year":"1979","journal-title":"Br J Clin Pharmac"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib151","first-page":"33","article-title":"A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain","volume":"36","author":"Adriaensen","year":"1985","journal-title":"Acta Anaesthesiol Belg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib152","first-page":"1306","article-title":"Intramuscular buprenorphine and morphine in the treatment of cancer pain. A controlled study","volume":"144","author":"Kjaer","year":"1982","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib153","first-page":"587","article-title":"Chronic analgesic study on buprenorphine action in cancer pain","volume":"33","author":"Ventafridda","year":"1983","journal-title":"Arzneim-Forsch\/Drug Res [Arzneimittelforschung]"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib154","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01731174","article-title":"Epidural opiates: Long-term experiences in cancer pain","volume":"63","author":"Zenz","year":"1985","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(87)90042-X","article-title":"Buprenorphine vs. morphine via the epidural route: A controlled comparative clinical study of respiratory effects and analgesic activity","volume":"29","author":"Pasqualucci","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib156","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002508-198906000-00004","article-title":"Continuous subcutaneous infusion of buprenorphine for cancer pain control","volume":"5","author":"Noda","year":"1989","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib157","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01402188","article-title":"Subarachnoid buprenorphine administered by implantable micropumps","volume":"102","author":"Francaviglia","year":"1990","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib158","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007998609110446","article-title":"An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly","volume":"10","author":"Nasar","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib159","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0149-2918(03)90019-1","article-title":"Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"25","author":"Sittl","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib160","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s100670200031","article-title":"Buprenorphine in a transdermal therapeutic system\u2014a new option","volume":"21","author":"B\u00f6hme","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib161","first-page":"15","article-title":"Buprenorphine TDS: The clinical development rationale and results","volume":"133","author":"Radbruch","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib162","first-page":"19","article-title":"Buprenorphine TDS: Use in daily practice, benefits for patients","volume":"133","author":"Radbruch","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib163","first-page":"A826","article-title":"Effectiveness of buprenorphine transdermal system (BTDS) compared with oxycodone\/acetaminophen and placebo in the treatment of patients with chronic back pain","volume":"95","author":"Spyker","year":"2001","journal-title":"Anesthesiology"},{"issue":"2 Suppl 1","key":"10.1016\/j.jpainsymman.2004.07.005_bib164","first-page":"12","article-title":"Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis","volume":"3","author":"Spyker","year":"2002","journal-title":"J Pain"},{"issue":"2 Suppl 1","key":"10.1016\/j.jpainsymman.2004.07.005_bib165","first-page":"14","article-title":"Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone\/acetaminophen in the treatment of patients with chronic low back pain","volume":"3","author":"Spyker","year":"2002","journal-title":"J Pain"},{"issue":"Suppl 4","key":"10.1016\/j.jpainsymman.2004.07.005_bib166","first-page":"S66","article-title":"Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain","volume":"50","author":"Spyker","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib167","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3959(97)00172-3","article-title":"Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain","volume":"74","author":"Benedetti","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib168","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.50.6.1837","article-title":"Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia","volume":"50","author":"Watson","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib169","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s001010050282","article-title":"Long-term treatment of chronic non-cancer pain with oral opioids","volume":"45","author":"Dertwinkel","year":"1996","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s004820050154","article-title":"Diagnostic and treatment measures in patients with sympathetically maintained pain","volume":"12","author":"Maier","year":"1998","journal-title":"Schmerz"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib171","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1468-2982.2001.00180.x","article-title":"SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report","volume":"21","author":"Sabatowski","year":"2001","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib172","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(98)00146-8","article-title":"Some new insights into the effects of opioids in phasic and tonic nociceptive tests","volume":"78","author":"McCormack","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib173","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0304-3959(97)03329-0","article-title":"Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice","volume":"70","author":"Womer","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib174","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/rapm-00115550-199823030-00015","article-title":"Six years of continuous intrathecal infusion of opioid and bupivacaine in the treatment of refractory pain due to intrapelvic extrusion of bone cement after total hip arthroplasty","volume":"23","author":"Dahm","year":"1998","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/bja\/52.4.453","article-title":"Double-blind comparison between fentanyl and buprenorphine in analgesic-supplemented anaesthesia","volume":"52","author":"Kay","year":"1980","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib176","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/bja\/52.10.1013","article-title":"Clinical effects of buprenorphine during and after operation","volume":"52","author":"McQuay","year":"1980","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib177","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1399-6576.1986.tb02496.x","article-title":"Perioperative buprenorphine: Do high dosages shorten analgesia postoperatively","volume":"30","author":"Pedersen","year":"1986","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib178","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/bja\/57.3.271","article-title":"Buprenorphine-supplemented anaesthesia. Influence of dose on duration of analgesia after cholecystectomy","volume":"57","author":"Obel","year":"1985","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib179","first-page":"1003","article-title":"Intraoperative administration of buprenorphine vs. methadone in postoperative pain management","volume":"42","author":"Carta","year":"1987","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib180","first-page":"345","article-title":"A comparison of buprenorphine and pethidine in analgesic supplemented anaesthesia","volume":"31","author":"Khan","year":"1990","journal-title":"Sing Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib181","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3565(25)10991-9","article-title":"Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination","volume":"261","author":"Preston","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib182","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3565(25)21335-0","article-title":"Drug discrimination in human postaddicts: Agonist-antagonist opioids","volume":"250","author":"Preston","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib183","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(25)22710-0","article-title":"Drug discrimination assessment of agonist-antagonist opioids in humans: A three-choice saline-hydromorphone-butorphanol procedure","volume":"271","author":"Preston","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib184","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0022-3565(24)38279-5","article-title":"Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure","volume":"289","author":"Jones","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib185","unstructured":"Subcommittee on Guidelines for Abuse Liability Assessment. Draft guidelines for abuse liability assessment. Subcommittee on Guidelines for Abuse Liability Assessment, Drug Abuse Advisory Committee, Food and Drug Administration, U.S. Public Health Service. Rockville, MD, June 1990."},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib186","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/clpt.1993.72","article-title":"Subjective and physiologic effects of intravenous buprenorphine in humans","volume":"53","author":"Pickworth","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib187","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/j.1360-0443.1991.tb01756.x","article-title":"Human drug abuse liability assessment: Opioids and analgesics","volume":"86","author":"Bigelow","year":"1991","journal-title":"Br J Addict"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib188","series-title":"Problems of drug dependence 1992. NIDA Research Monograph No. 132","first-page":"335","article-title":"Detectability of buprenorphine dose alterations in opioid-dependent humans","author":"Amass","year":"1993"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib189","unstructured":"DAWN Emergency Department Reports and Tables. Available at www.samhsa.gov\/oas\/dawn\/final2k1edtrends\/publishedtables\/pubtablesch2.xls Table 2.8.0. Accessed September 21, 2003."},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib191","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/clpt.1990.67","article-title":"Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal","volume":"47","author":"Fudala","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib192","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0376-8716(90)90144-4","article-title":"Opioid antagonist challenges in buprenorphine maintained patients","volume":"25","author":"Kosten","year":"1990","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib193","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0740-5472(90)90035-O","article-title":"Depressive symptoms during buprenorphine treatment of opioid abusers","volume":"7","author":"Kosten","year":"1990","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib194","series-title":"Problems of drug dependence 1987. NIDA Research Monograph","first-page":"289","article-title":"Buprenorphine: Pilot trials in borderline patients and opiate dependence-treatment of a common disorder?","author":"Resnick","year":"1988"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib195","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/0006-3223(90)90619-D","article-title":"Buprenorphine responders","volume":"28","author":"Mongan","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib196","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib197","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(82)90727-9","article-title":"Antidepressant effects of buprenorphine","volume":"2","author":"Emrich","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib198","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: Action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann NY Acad Sci"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2004.07.005_bib199","first-page":"39","article-title":"Treatment-resistant depression: Definition and treatment approaches","volume":"51","author":"Nierenberg","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib200","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","article-title":"Antipsychotic effect of buprenorphine in schizophrenia","volume":"144","author":"Schmauss","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib201","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hup.470060113","article-title":"Buprenorphine and schizophrenia","volume":"6","author":"Groves","year":"1991","journal-title":"Human Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib202","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002508-200203000-00002","article-title":"Major depression and insomnia in chronic pain","volume":"18","author":"Wilson","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0033-3182(81)73478-9","article-title":"The depression-pain syndrome and its response to antidepressants","volume":"22","author":"Lindsay","year":"1981","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0376-8716(90)90078-S","article-title":"Safety and side-effects of buprenorphine in the clinical management of heroin addiction","volume":"26","author":"Lange","year":"1990","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib206","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib207","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0376-8716(92)90061-G","article-title":"Buprenorphine alone and in combination with naloxone in non-dependent humans","volume":"30","author":"Weinhold","year":"1992","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib208","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1989.10","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"45","author":"Gal","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib209","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: Partial agonist and blockade effects","volume":"274","author":"Walsh","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-3565(24)36921-6","article-title":"Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers","volume":"282","author":"Zacny","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib211","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib212","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00544557","article-title":"Psychomotor, respiratory, and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers","volume":"33","author":"Saarialho-Kere","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib213","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1989.tb05393.x","article-title":"Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac","volume":"27","author":"MacDonald","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib214","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/jnp.13.4.527","article-title":"Less driving impairment on buprenorphine than methadone in drug-dependent patients?","volume":"13","author":"Soyka","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10550490050148099","article-title":"Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine","volume":"9","author":"Petry","year":"2000","journal-title":"Am J Addict"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib216","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0168-8278(00)00049-0","article-title":"Hepatitis after intravenous buprenorphine misuse in heroin addicts","volume":"34","author":"Berson","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib217","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-8278(00)00050-7","article-title":"Mechanisms for experimental buprenorphine hepatotoxicity: Major role of mitochondrial dysfunction versus metabolic activation","volume":"34","author":"Berson","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib218","series-title":"Problems of drug dependence, 2002. Proceedings of the 64th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 183","first-page":"134","article-title":"French experience with buprenorphine","author":"Auriacombe","year":"2003"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib219","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/j.1875-9114.1991.tb03604.x","article-title":"Prolonged nausea and vomiting associated with buprenorphine","volume":"11","author":"Fullerton","year":"1991","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","article-title":"Deaths involving buprenorphine: A compendium of French cases","volume":"121","author":"Kintz","year":"2001","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib221","first-page":"1433","article-title":"Local complications after intravenous injection of dissolved tablets of buprenorphine","volume":"26","author":"Decocq","year":"1997","journal-title":"Presse Med"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib222","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/0003-4819-130-6-199903160-00011","article-title":"Myocardial infarction associated with buprenorphine","volume":"130","author":"Cracowski","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib223","first-page":"93","article-title":"The effect of doxapram on buprenorphine induced respiratory depression","volume":"28","author":"Orwin","year":"1977","journal-title":"Acta Anaesthesiol Belg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib224","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs. buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"J Amer Med Assoc"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: A report of 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib226","series-title":"Buprenorphine therapy of opiate addiction","first-page":"109","article-title":"Buprenorphine-related deaths","author":"Kintz","year":"2002"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib227","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0091-3057(88)90128-1","article-title":"The psychopharmacologic and prolactin response after large doses of naloxone in man","volume":"30","author":"Kumor","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib228","first-page":"171","article-title":"A double blind comparison of buprenorphine and morphine in conscious subjects following administration by the intramuscular route","volume":"27","author":"Orwin","year":"1976","journal-title":"Acta Anaesthesiol Belg"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib229","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00000542-198603000-00018","article-title":"Early respiratory depression resistant to naloxone following epidural buprenorphine","volume":"64","author":"Knape","year":"1986","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib230","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(73)91879-5","article-title":"Treatment of drug overdosage with naloxone, a specific narcotic antagonist","volume":"1","author":"Evans","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib231","doi-asserted-by":"crossref","unstructured":"Reckitt Benckiser Proprietary Limited (West Ryde, NSW, Australia). Temgesic Product Information 2004.","DOI":"10.1016\/S1351-4210(04)00124-6"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib232","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0196-0644(05)80200-8","article-title":"Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: A pilot study","volume":"22","author":"Kaplan","year":"1993","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib233","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/105504999305983","article-title":"Methadone overdose in an opiate-naive patient","volume":"8","author":"Atdjian","year":"1999","journal-title":"Am J Addict"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib234","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00004714-200204000-00024","article-title":"Conservative management with naltrexone of an iatrogenic methadone overdose in an opiate-na\u00efve patient","volume":"22","author":"Dhopesh","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib235","first-page":"219","article-title":"Intra- and postoperative interactions between the 2 opioids fentanyl and buprenorphine","volume":"35","author":"Muller","year":"1986","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib236","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1399-6576.1988.tb02772.x","article-title":"Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia","volume":"32","author":"Boysen","year":"1988","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib237","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0304-3959(88)90120-0","article-title":"The effect of buprenorphine on the analgesic and respiratory depressant effects of pethidine: A preliminary study","volume":"34","author":"Vedig","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib238","first-page":"515","article-title":"Antihistaminc-opioid combination: Effect on locomotor activity in mice","volume":"40","author":"Sansone","year":"1988","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib239","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1360-0443.1995.tb03504.x","article-title":"Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992","volume":"90","author":"Hammersley","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2044.1985.tb10903.x","article-title":"Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine","volume":"40","author":"Schmidt","year":"1985","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib241","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(98)00008-8","article-title":"Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts","volume":"50","author":"Fudala","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib242","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib243","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0022-3565(25)20670-X","article-title":"Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans","volume":"278","author":"Schuh","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib244","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3565(25)11174-9","article-title":"Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers","volume":"261","author":"Strain","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib245","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0022-3565(25)24449-4","article-title":"Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone","volume":"272","author":"Strain","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib246","first-page":"257","article-title":"Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors","volume":"26","author":"Iribarne","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib247","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0376-8716(00)80007-1","article-title":"Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART","volume":"60","author":"Carrieri","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib248","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1472-8206.1998.tb00941.x","article-title":"In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine","volume":"12","author":"Iribarne","year":"1998","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib249","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0376-8716(91)90037-Y","article-title":"The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine","volume":"27","author":"Witkin","year":"1991","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib250","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/0024-3205(91)90289-N","article-title":"Antagonism of acute cocaine toxicity by buprenorphine","volume":"49","author":"Shukla","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib251","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s002130050417","article-title":"Theory and statistics of detecting synergism between two active drugs: Cocaine and buprenorphine","volume":"133","author":"Tallarida","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib252","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002130050416","article-title":"Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat","volume":"133","author":"Kimmel","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib253","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.2042-7158.1993.tb05668.x","article-title":"Buprenorphine-cocaine interactions in mice: Effect on locomotor activity and hole-dipping behaviour","volume":"45","author":"Jackson","year":"1993","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib254","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004714-199304000-00002","article-title":"Acute interactions of buprenophine with intravenous cocaine and morphine: An investigational new drug phase I safety evaluation","volume":"13","author":"Teoh","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib255","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","article-title":"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations","volume":"155","author":"Reynaud","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib256","first-page":"185","article-title":"Prison, drugs and death: Two deaths due to overdoses in a prison environment","volume":"41","author":"Tracqui","year":"1998","journal-title":"J M\u00e9d L\u00e9gale Droit M\u00e9d"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib257","first-page":"557","article-title":"Acute poisoning by high-dosage buprenorphine-based substitution treatment. 29 clinical cases\u201420 fatal cases","volume":"27","author":"Tracqui","year":"1998","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib258","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1520\/JFS14667J","article-title":"Fatal intoxication following self-administration of a massive dose of buprenorphine","volume":"45","author":"Gaulier","year":"2000","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib259","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/appi.ajp.157.7.1164","article-title":"Lack of interaction of buprenorphine with flunitrazepam metabolism","volume":"157","author":"Kilicarslan","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib260","first-page":"777","article-title":"Temgesic abuse","volume":"96","author":"Harper","year":"1983","journal-title":"NZ Med J"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib261","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1360-0443.1988.tb00536.x","article-title":"Buprenorphine abuse among opiate addicts","volume":"83","author":"O'Connor","year":"1988","journal-title":"Br J Addict"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib262","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1360-0443.1989.tb00589.x","article-title":"Buprenorphine and temazepam abuse by drug takers in Glasgow\u2014an increase","volume":"84","author":"Sakol","year":"1989","journal-title":"Brit J Addict"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib263","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1300\/J069v10n03_02","article-title":"The use of buprenorphine and temazepam by drug injectors","volume":"10","author":"Lavelle","year":"1991","journal-title":"J Addict Dis"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib264","first-page":"18","article-title":"Subgroups of addicted buprenorphine-consuming patients","volume":"8","author":"Segui","year":"1991","journal-title":"An Med Internat"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib265","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1360-0443.1992.tb02739.x","article-title":"Predicting initiation to and cessation of buprenorphine and temazepam use amongst adolescents","volume":"87","author":"Hammersley","year":"1992","journal-title":"Br J Addict"},{"issue":"Suppl 1","key":"10.1016\/j.jpainsymman.2004.07.005_bib266","first-page":"S13","article-title":"Transdermal buprenorphine: Abuse potential assessment in non-opioid-dependent volunteers","volume":"63","author":"Becker","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib267","series-title":"Drug treatment of cancer pain in a drug-oriented society","first-page":"1","article-title":"Does treatment of cancer pain with narcotics produce junkies?","author":"Schuster","year":"1989"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib268","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0304-3959(89)90097-3","article-title":"Opioid pseudoaddiction\u2014an iatrogenic syndrome","volume":"36","author":"Weissman","year":"1989","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2004.07.005_bib269","series-title":"Methadone treatment for opioid dependence","first-page":"281","article-title":"Other medications for opioid dependence","author":"Johnson","year":"1999"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392404005664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392404005664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:37Z","timestamp":1760129737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392404005664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":269,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0885392404005664"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.07.005","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine: Considerations for Pain Management","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}